Pleiotropic effects of ARB on dyslipidemia

Current Vascular Pharmacology

Volumn 9, Issue 2, 2011, Pages 129-135

  Taguchi, Isao ^a   Inoue, Teruo ^a   Kikuchi, Migaku ^a   Toyoda, Shigeru ^a   Arikawa, Takuo ^a   Abe, Shichiro ^a   Node, Koichi ^b  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b SAGA UNIVERSITY   (Japan)

Author keywords

ARB; Dyslipidemia; Lipid metabolism; PPAR

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ATENOLOL; CANDESARTAN; EPROSARTAN; FELODIPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIFEDIPINE; OLMESARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; ROSIGLITAZONE; TELMISARTAN; TRIACYLGLYCEROL; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; GLUCOSE METABOLISM; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PLEIOTROPY; TREATMENT DURATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL; DYSLIPIDEMIAS; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEINS;

EID: 79951686040     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016111794519336     Document Type: Article

References (38)

1. Kannel WB. Hypertension as a risk factor for cardiac events: epidemiologic results of long-term studies. J Cardiovasc Pharmacol 1993; 21: 27-37.
2. Fedder DO, Koro CE, L'Italien GJ. New National cholesterol edication program III guidelines for primary prevention lipid-lowering drug therapy. Circulation 2002; 105: 152-6.
3. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with sinvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360: 7-22.
4. Kaplan NM. The deadly quartet. Arch Intern Med 1989; 149: 1514-20.
5. Siragy HM, Bedigian M. Mechanism of action of angiotensinreceptor blocking agent. Curr Hypertens Rep 1999; 1: 289-95.
6. Siragy HM. AT(1) and AT(2) receptors in the kedny: role in disease and treatment. Am J Kidney Dis 2000; 36 (Suppl 1): S4-9.
7. Weir MR, Dzau VJ. The rennin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999; 12(Pt 3): 205S-13.
8. Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 2002; 113: 409-18.
9. Schmieder RE. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens 2005; 18(Pt 1): 720-30.
10. Olsen MH, Wachtell K, Beevers G, et al. Effects of losartan compared with atenolol on lipids in patients with Hypertension and left ventricular hypertrophy: the Losartan Intervention For Endopoint reduction in hypertension study. J Hypertens 2009; 27: 567-74.
11. Appel GB, Radhakrishnan J, Avram MM, et al.; for RENAAL Study Investigators. Analysis of metabolic parameters as predictors of risk in the RENAAL Study. Diabetes Care 2003; 26: 1402-7.
12. Julis S, Kjeldsen SE, Weber M, et al; for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE rabdomised trial. Lancet 2004; published online Available at: http://image.thelancet.com/extras/04art4187web.pdf
13. Lindoholm LH, Person M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabilic outcome during 1 tear in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profiles in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563-74.
14. Inoue T, Node K. Telmisartan as a metabolic sartan for targeting vascular failure. Expert Opin Pharmacother 2008; 9: 1397-406.
15. Derosa G, Cicero AFG, Bertone G, et al. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic ststem on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabete mellitus and mild hypertension: a 12 month, randomized, double blind study. Clin Ther 2004; 26: 1228-36.
16. Negro R, Formoso G, Hassen H. The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest 2006; 29: 957-61.
17. Sasaki T, Noda Y, Yasuoka Y, et al. Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metablic syndrome. Hypertens Res 2008; 31: 921-9.
18. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27: 457-64.
19. Derosa G, Fogari E, D'Angelo A, et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007; 32: 261-8.
20. Inoue T, Morooka T, Moroe K, Ikeda H, Node K. Effect of telmisartan on cholesterol levels in patients with hypertension - Saga Telmisartan Aggressive Research (STAR)-. Horm Metab Res 2007; 39: 372-6.
21. Kyvelou SM, Vyssoulis GP, Karpanou EA, et al. Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol 2006; 47: 29-30.
22. Lee C, Olson P, Evans RM. Lipid metabolism, metabolic disease, and peroxisome proliferator-activated receptors. Endocrinology 2003; 1446: 2201-7.
23. Folli F, Saad MJ, Velloso L, et al. Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes 1999; 107: 133-9.
24. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993-1002.
25. Schupp M, Clemenz M, Gineste R, et al. Molecular characterization of new selective peroxisome proliferators-activated receptor γ modulators with angiotensine receptor blocking activity. Diabetes 2005; 54: 3442-52.
26. Gervois P, Torra IP, Fruchart JC, Staels B. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin Chem Lab Med 2000; 38: 3-11.
27. Von Eckardstein A, Nofer J, Assmann G. High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001; 21: 13-27.
28. Hoekstra M, Kruijt JK, van Eck M, van Berkel TJC. Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells. J Biol Chem 2003; 278: 25448-53.
29. Takata Y, Chu V, Collins AR, et al. Transcriptional repression of ATP-binding cassette transporter A1 gene in macrophages: a novel atherosclerotic effect of angiotensin II. Circ Res 2005; 97: e88-96.
30. Repa JJ, Turley SD, Lobaccaro JA, et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 2000; 289: 24-9.
31. Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjuscent ABC transporters. Science 2000; 290: 1771-5.
32. Francis GA, Annicotte J, Auwerx J. Liver X receptors: Xcreting Xol to combat atherosclerosis. Trends Mol Med 2002; 8: 455-8.
33. Clemenz M, Frost N, Schupp M, et al. Liver-specific PPAR- γ target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes 2008; 57: 1405-13.
34. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR γ -modulating activity. Hypertension 2004; 43: 993-1002.
35. Kurtz TW, Pravenec M. Antidiabetic mechanisms of ACE inhibitors and AII receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004; 22: 2253-61.
36. Keidar S, Kaplan M, Hoffman A, Aviram M. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 1995; 115: 201-15.
37. Nickenig G, Jung O, Strehlow K, et al. Hypercholesterolemia is associated with enhanced angiotensin AT1 receptor expression. Am J Physiol 1997; 272: 2701-7.
38. Nickenig G, Baumer AT, Temur Y, Kebben D, Jockenhövel F, Böhm M. Dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 1999; 100: 2131-4.